This article is more than 5 years old. Information may no longer be current.
VIDEO: Novel HF therapies show promise
Click Here to Manage Email Alerts
ORLANDO, Fla. — New research on novel therapies for patients with HF presented at the American Heart Association Scientific Sessions opens the door for larger phase 3 trials, James L. Januzzi Jr., MD, said in a video interview.
“The HF space has become very crowded these days with new drugs,” said Januzzi, the Roman W. DeSanctis Endowed Distinguished Clinical Scholar in Medicine and director of the Dennis and Marilyn Barry Fellowship in Cardiology Research at Massachusetts General Hospital.
Januzzi discussed results of the phase 2 SOCRATES-REDUCED and COSMIC-HF studies. In SOCRATES-REDUCED, vericiguat (Bayer/Merck), a soluble guanylate cyclase stimulator, did not significantly influence changes in N-terminal pro-B-type natriuretic peptide in patients with worsening HF. In COSMIC-HF, omecamtiv mecarbil (Amgen/Cytokinetics), a selective myosin activator, was associated with a number of cardiac structural and functional improvements in patients with chronic HF.
“These two agents are quite interesting,” Januzzi said.